Buy Local, Buy Wisconsin Grants 2025

The FY24 BCRP Clinical Research Extension Award is designed to maximize the impact of previously funded breast cancer clinical studies by extending or expanding data collection, follow-up, and analysis. This mechanism directly addresses the loss of knowledge resulting from early trial termination, limited patient follow-up, or inadequate sample/data collection and analysis. The BCRP emphasizes the invaluable contributions of patient specimens and data, aiming to ensure that research maximizes the impact of these contributions toward saving lives and accelerating progress in ending breast cancer. Projects proposing to conduct new clinical trials will not be supported, focusing instead on leveraging existing clinical study infrastructure and data. The core impact goal of the award is to extend or affect the impact of a previously funded clinical trial or study, or to generate new impact toward ending breast cancer. Target beneficiaries include breast cancer patients whose contributions are utilized, and ultimately, active-duty Service Members, Veterans, military beneficiaries, and the American public who stand to benefit from advancements in breast cancer research. The program encourages collaborations between researchers at military/Veteran institutions and non-military institutions to leverage unique resources and access to diverse clinical populations, ensuring the research is relevant to the military community and the general public. Priorities and focuses for the proposed research, although not all-inclusive, include deeper molecular analysis of clinical samples, new correlative studies, biomarker validation, or continuing clinical follow-up of patients in open or completed trials. The research may be hypothesis-testing, -generating, or designed to create clinically annotated and molecularly characterized experimental platforms, such as patient-derived models. A required component is the involvement of two or more breast cancer consumer advocates—individuals diagnosed with breast cancer and active in advocacy organizations—who must provide objective input on the research design and its potential impact for individuals with, or at risk for, breast cancer. Innovation is not a required criterion for this award. Expected outcomes include generating meaningful hypotheses or supporting valid conclusions through statistically appropriate sample sizes and robust data analysis. Applicants must outline a data-sharing plan to ensure the scientific community has access to experimental platforms, molecular, and other data generated. The award encourages meaningful and productive partnerships, offering a Partnering PI Option with a higher funding limit ($6M vs. $5M for a single PI) to support collaborative efforts where both PIs bring distinct and critical expertise, reinforcing a strategic priority to foster team science in complex research questions. The CDMRP expects to allot approximately $18.6 million to fund about two applications.